Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Asthma study aims to unlock personalized treatments for chinese patients

NCT ID NCT06419413

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 4 times

Summary

This observational study is enrolling 355 adults with asthma in China to describe their clinical features, treatment patterns, and biological markers. Researchers will analyze lung function, imaging, and blood biomarkers to identify distinct asthma subtypes. The goal is to gather knowledge that could support the development of personalized treatment strategies for this population in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help identify asthma subtypes in Chinese patients, paving the way for more personalized treatment strategies in the future.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve health. Results may not apply to other populations or lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 355 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A total of up to 355 participants will be recruited and enrolled into Cohort A (healthy participants), Cohort B (mild asthmatics), Cohort C (moderate to severe asthmatics), and Cohort D (Exacerbation asthmatics). Enrolment will be monitored to, 1) ensure at least 20 current smoker or ex-smoker in Cohort A; 2) ensure at least 40 male participants aged 40 years old or above in Cohort A.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 75 years of age * acceptable FEV1 (according to ATS and ERS) * compliance with study procedures All Asthma Cohorts * physician diagnosed Asthma greater or equal to 3 months prior to screening visit Exclusion Criteria: * history of alcohol or drug abuse within the past year * pregnant at time of an assessment * has an altered mental status at the time of informed consent * receipt marketed or investigational biologic(s) within 3 months or 5 half-lives prior to visit 1, whichever is longer * history or current upper or lower respiratory infection or symptoms within 2 weeks of baseline assessments * terminal diseases and/or organ failure or participants otherwise considered not appropriate for the study participation * Receipt LTRAs or 5-lipoxygenase (5-LO) inhibitors (eg zileuton and montelukast) within 1 month or 5 half-lives prior to baseline, whichever is longer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    21 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Chengdu, Sichuan, China

  • Research Site

    NOT_YET_RECRUITING

    Beijing, China

  • Research Site

    NOT_YET_RECRUITING

    Changsha, China

  • Research Site

    NOT_YET_RECRUITING

    Dongguan, China

  • Research Site

    NOT_YET_RECRUITING

    Foshan, China

  • Research Site

    NOT_YET_RECRUITING

    Guangzhou, China

  • Research Site

    NOT_YET_RECRUITING

    Hainan, China

  • Research Site

    NOT_YET_RECRUITING

    Hohhot, China

  • Research Site

    NOT_YET_RECRUITING

    Huizhou, China

  • Research Site

    NOT_YET_RECRUITING

    Kunming, China

  • Research Site

    NOT_YET_RECRUITING

    Nanjing, China

  • Research Site

    NOT_YET_RECRUITING

    Nanning, China

  • Research Site

    NOT_YET_RECRUITING

    Shanghai, China

  • Research Site

    NOT_YET_RECRUITING

    Shenyang, China

  • Research Site

    RECRUITING

    Taiyuan, China

  • Research Site

    NOT_YET_RECRUITING

    Wenzhou, China

  • Research Site

    RECRUITING

    Wuhan, China

  • Research Site

    RECRUITING

    Xi'an, China

  • Research Site

    NOT_YET_RECRUITING

    Xuzhou, China

  • Research Site

    NOT_YET_RECRUITING

    Zhanjiang, China

  • Research Site

    NOT_YET_RECRUITING

    Zhaoqing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.